BCL2 and non-small cell lung carcinoma: P2pal-18S largely promoted gefitinib to up-regulate Bax expression and down-regulate Bcl-2 expression in PC-9 and PC-9-GR cells, and therefore the Bcl-2/Bax ratio was notably reduced in NSCLC cells treated with P2pal-18S and gefitinib.